"The New Drug Application 22-343 provides for the use of Efavirenz+Lamivudine+Tenofovir Disoproxil Fumarate tablets, 600mg/300mg/300mg alone or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults and adolescents aged more than 16 years of age and weighing at least 40 kg," the drugmaker said in a filing to the ... (more)
http://www.pmpnews.com/news/aurobindo-pharma-receives-us-fdas-tentative-nod-aids-drug
http://www.pmpnews.com/news/aurobindo-pharma-receives-us-fdas-tentative-nod-aids-drug
No comments:
Post a Comment